The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Evaluating the feasibility of segmentectomy in clinical stage IA3 NSCLC
Rene Petersen, MD, PhD, Rigshospitalet, Copenhagen, Denmark, comments on the potential expansion of the indication for segmentectomy in non-small cell lung cancer (NSCLC) beyond the current 2 cm guideline. Studies have found found similar survival outcomes between patients with NSCLC between 2-3 cm and those with tumors less than 2 cm, suggesting that segmentectomy may be a viable option for well-selected patients. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
